Pharmatio GmbH, already established in the monitoring and site liaison of clinical trials, has restructured its services. With Clinical Trial Liaison, the sponsors of clinical trials can ensure the patient recruitment and effectiveness of their clinical trials. The Clinical Trial Task Force masters difficult or unforeseen challenges in clinical trials, and High Quality Monitoring ensures that Pharmatio ensures all-time inspection readiness of clinical trial sites.
BIO Europe with new record numbers
Latest NewsDespite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering event again see a record number of participants.
Ayoxxa: Bridging the gap
AppointmentsCologne-based biotech Ayoxxa Biosystems GmbH announces that Rodney Turner has assumed duties as the interim CEO. Prior CEO Andreas Schmidt has stepped down.
Performance in Clinical Trials: Pharmatio GmbH with new Portfolio
Sponsored PublicationsPharmatio GmbH, already established in the monitoring and site liaison of clinical trials, has restructured its services. With Clinical Trial Liaison, the sponsors of clinical trials can ensure the patient recruitment and effectiveness of their clinical trials. The Clinical Trial Task Force masters difficult or unforeseen challenges in clinical trials, and High Quality Monitoring ensures that Pharmatio ensures all-time inspection readiness of clinical trial sites.
Merus: Changes in management
AppointmentsDutch immuno-oncology company Merus has appointed John Crowley its Chief Financial Officer. Former CFO Shelley Margetson has been elevated to Chief Operating Officer.
TxCell: Cell engineering virtuoso
AppointmentsFrench cellular immunotherapy company TxCell has hired ex-Novartis Lab Head Li Zhou to lead its CAR-Treg programmes. Zhou was appointed Vice President Cell Engineering in October.
AZ withdraws lung cancer drug from EU lead market
Latest NewsAfter AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest of lung cancer patients.
Bioregions deliver action plan blueprint
Latest NewsWhile DG Research has delayed its update on the European Bioeconomy Strategy and Action Plan until next June, the Central and Eastern Bioregions presented a blueprint that proposes key actions aimed at integrating the goals of the European Commissions circular economy and the bioeconomy strategies.
Targovax: CFO turned CEO
AppointmentsNorwegion immuno-oncology play Targovax has promoted Øystein Soug, previously the companys Chief Financial Officer, to the role of Chief Executive Officer. He succeeds Gunnar Gårdemyr, who has stepped down.
Early Certainty: Quality first!
OpinionGermany lagging behind in stem cell research
Latest NewsA new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their investments into the future field.